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Objective: The purpose of this study was to review our experience over the last decade with the dorsalis pedis bypass for
ischemic limb salvage in patients with diabetes mellitus.
Methods: The study was a retrospective analysis of a computerized vascular registry and chart review. From January 10,
1990 to January 11, 2000, 1032 bypasses to the dorsalis pedis artery were performed in 865 patients (27.6% of the 3731
lower extremity arterial bypass procedures performed in that time period). Five hundred ninety-seven patients (69%) were
male, with a mean age of 66.8 years. Ninety-two percent had diabetes mellitus. All procedures were done for limb salvage.
Conduits included 317 nonreversed saphenous vein (30.7%), 273 in situ (26.4%), 235 reversed vein (22.8%), 170 arm
vein (16.5%), 35 other vein (3.4%), and two polytetrafluoroethylene (0.2%) grafts. The inflow arteries were as follows:
294 common femoral (28.5%), 550 popliteal (53.2%), 114 superficial femoral (11%), and 74 other (7.2%).
Results: The mortality rate within 1 month of surgery was 0.9%, and 42 grafts (4.2%) failed in the same interval, although
13 were successfully revised. In a follow-up period that ranged from 1 to 120 months (mean, 23.6 months), primary
patency, secondary patency, limb salvage, and patient survival rates were 56.8%, 62.7%, 78.2%, and 48.6%, respectively at
5 years and 37.7%, 41.7%, 57.7%, and 23.8% at 10 years. Both polytetrafluoroethylene grafts failed in less than 1 year.
Primary graft patency was worse in female patients (46.5% female versus 61.6% male at 5 years; P < .009) but better in
patients with diabetes (65.9% diabetes mellitus versus 56.3% non-diabetes mellitus at 4 years; P < .04). Saphenous vein
grafts performed better than all other conduits with a secondary patency rate of 67.6% versus 46.3% at 5 years (P <
.0001). Multivariate analysis showed that length of stay greater than 10 days and dorsalis pedis bypass for the surgical
indication of previous graft occlusion were independently predictive of worse graft patency at 1 year and use of saphenous
vein as conduit was predictive of better patency.
Conclusion: Dorsalis pedis bypass is durable with a high likelihood of ischemic foot salvage over many years. Saphenous
vein is the preferred conduit when available. Short vein grafts from distal inflow sites are possible in more than 50% of
cases. These results justify the routine use of pedal arterial reconstruction for patients with diabetes with ischemic foot
complications. (J Vasc Surg 2003;37:307-15.)
Dorsalis pedis (DP) artery bypass is particularly well
suited for the treatment of ischemic foot complications in
patients with diabetes mellitus because of the characteristic
pattern of atherosclerosis seen in these patients.1 We have
previously reported our results with DP bypass in nearly
400 patients2 and also its applicability in patients with
ischemia complicated by foot infection3 and in healing
ischemic heel ulcers.4 In the last 10 years, DP bypass has
been the single most commonly performed lower extremity
arterial reconstruction in our practice, comprising nearly
30% of all arterial reconstructions performed.
In spite of our satisfaction with this procedure, some
investigators continue to prefer more traditional popliteal
and tibial arterial reconstructions.5-8 The purpose of this
study was to review our ongoing experience, now exceed-
ing 1000 procedures, with follow-up extending to 10 years,
and to reassess durability, limb salvage, and patient factors
that may impact results.
MATERIALS AND METHODS
Demographic data, indications for surgery, comorbid
conditions, specific details about the surgical procedure,
complications, and outcome at discharge and during the
follow-up period were all prospectively entered into our
vascular surgery database. The database was retrospectively
queried for this study. All data are presented in accordance
with the revised reporting standards of the Joint Council of
the Society for Vascular Surgery and the American Associ-
ation of Vascular Surgery.9 Grafts were considered patent if
a palpable pulse was present over the graft at the level of the
dorsal foot. Limb salvage was defined as preservation of
enough of the foot to allow ambulation of the patient
without the need for a limb prosthesis and included feet
requiring toe, ray, or transmetatarsal amputations or partial
or complete calcaneous resections10,11 after pedal bypass.
Syme’s and Chopart’s amputations were not performed in
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this patient population. Death during the follow-up period
was determined from queries to the Social Security Death
Index. After discharge, patients were followed at regular
intervals, usually every 3 months during the first year, every
6 months in the second year, and annually thereafter.
Follow-up was more frequent in patients with open wounds
and after repeat surgical procedures, such as graft revisions
or bypasses on the other limb. Graft patency was deter-
mined and recorded by the attending surgeon. In the later
years of the study, many grafts, particularly arm veins, were
followed with duplex ultrasonography, although this was
not done routinely. When the registry contained incom-
plete follow-up information, patient charts were reviewed
or patients were contacted by phone to determine the
current status of their pedal graft and foot.
Statistics were performed with the aid of Statview 5.0
software (SAS Institute, Inc, Cary, NC). Categoric vari-
ables were compared with the 2 test, and continuous
variables with the Student t test. Factors found to be
significant in univariate analysis were then studied in mul-
tivariate logistic regression. Independent variables were
assumed to be significant if the Wald test returned a P value
of less than .05. Survival rates were calculated with the
Kaplan-Meier product-limit method. The Mantel-Cox log-
rank test was used to compare survival curves among differ-
ent groups.
Diagnosis and surgical technique. Our approach to
DP bypass has been described previously.12 We continue to
rely on comprehensive intraarterial digital subtraction an-
giography13 for imaging of the circulation from the renal
arteries to the base of the toes in all patients with limb
ischemia. Proper imaging of the foot vessels requires views
in two planes, usually anteroposterior and lateral, to fully
appreciate the quality of the DP artery and its potential use
as an outflow target artery. Magnetic resonance angiogra-
phy was used infrequently in those patients unable to have
contrast because of allergies or severe renal insufficiency.
“Blind” exploration of a DP artery, not seen on angiogra-
phy but thought to be patent on the basis of an audible
Doppler signal heard in the foot, was performed when
appropriate, although this was done much less frequently in
the later years of this study because of improvements in
radiographic equipment and the experience of our radiol-
ogists in imaging foot vessels.
The decision to perform a DP bypass is made on the
basis of anatomic and clinical factors. Our preference is to
restore a palpable foot pulse when possible in patients with
diabetes with any tissue loss on the basis of our observations
that the endpoint most reliably leads to healing and foot
salvage in the milieu of the compromised biology of the
ischemic diabetic foot. If no more proximal outflow target
artery will achieve that goal, we will preferentially bypass to
the DP artery. In situations of rest pain without tissue loss,
the DP artery was chosen as the outflow target vessel when
it was the best quality vessel for bypass or the only available
outflow vessel as determined on the arteriogram. In cir-
cumstances where a femoral-popliteal or tibial arterial by-
pass would restore a palpable foot pulse and tissue loss was
the indication, DP bypass was not performed. In cases of
tissue loss or gangrene, DP bypass was often chosen in
preference to a patent peroneal artery. Bypasses to the
peroneal artery were performed in preference to the DP
artery when the DP artery was a poorer quality vessel on the
arteriogram or when the vein conduit available was of
inadequate length to reach the DP artery. DP bypass was
avoided in cases of severe dorsal foot infection and when
the indication for surgery was claudication.
Saphenous vein grafts were harvested or exposed
through open incisions. We believe this is the simplest and
most expedient approach and best identifies potentially
diseased, narrowed, or poor-quality conduit. Minimization
of serious wound complications requires the avoidance of
skin flaps during exposure or the excision of inadvertent
flaps before closure. Control of preexisting infection, me-
ticulous hemostasis, and wound closure without excessive
tension are other important principles.
Our strategy14 is designed to simplify the procedure
and minimize the use of prosthetic grafts. Briefly, the
principles include the use of distal inflow sites and short,
translocated, saphenous vein grafts whenever possible.
When bypasses originated from the common femoral artery
and the saphenous vein was intact, veins were left in situ.
Most in situ vein grafts were prepared with an angioscope
and pump irrigation system15,16 inserted into the proximal
end of the vein graft with a long flexible valvulotome17
inserted from the distal end before completion of the
anastomoses. Use of a pump irrigation system during an-
gioscopy improved clarity and reduced the time of the
study and the volume of crystalloid infused.
When saphenous vein was unavailable or unusable, our
first choice for alternative vein conduit was arm vein.18
When arm veins were not available, lesser saphenous vein
was used if the caliber and quality was adequate for bypass.
Composite grafts comprised of different vein segments also
were occasionally used. The quality of arm and composite
vein conduits was also determined with angioscopy.19
When vein was limited, every effort was made to originate
the graft from a distal inflow site even if the superficial
femoral artery had some disease as long as it was not
believed to be hemodynamically significant. In a few cases,
a simultaneous femoral popliteal bypass with a prosthetic
graft and a popliteal to DP bypass with vein were con-
structed in sequence. Previous aortofemoral or iliofemoral
reconstructions were also used for inflow for some patients.
Exposure of the DP artery is accomplished with a
longitudinal foot incision, placed directly over the Doppler
signal of the artery on the dorsal foot. This is generally
slightly lateral to the extensor hallucis longus tendon. The
artery may occasionally be in a much more lateral location,
underscoring the importance of carefully examining the
preoperative arteriogram and using the Doppler to pre-
cisely locate the artery before making the incision. When in
situ vein grafts are performed, the graft is tunneled proxi-
mally to and never through the resulting skin bridge be-
tween the parallel foot incisions required to expose the
artery and dorsal foot extension of the saphenous vein. In
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our experience, foot wounds can be closed primarily, with-
out the use of advancement or rotational flaps, but must be
meticulous, avoiding excessive tension. A single layer of a
4-0 or 5-0 absorbable subcuticular suture or a simple
interrupted skin suture is usually adequate. Completion
arteriography is rarely performed in our practice. We have
previously shown20 that most technical failures in our pro-
cedures occur as a result of problems with the conduit,
which are best avoided in our experience with the use of
angioscopy in preparation of the vein.
After surgery, patients are placed on aspirin 81 mg a day
indefinitely and 5000 units of subcutaneous injections of
unfractionated heparin every 12 hours until discharge. In
our experience, many wound problems start as a result of
significant leg edema, which nearly always accompanies DP
bypass. Reduction of postoperative edema is therefore crit-
ical in reduction of wound complications. Most patients are
restricted from weight bearing on the foot for 2 to 7 days or
longer, depending on how well foot wounds are healing
and where other ulcers are located on the foot. Resumption
of ambulation should be gradual and may require the use of
partial weight bearing on crutches or a walker and the use of
open-toe postoperative sandals until the foot is healed. The
leg should be elevated frequently in the first few weeks to
reduce edema. Elastic wraps are often helpful. In spite of
these measures, many foot and leg wounds will have some
difficulties with healing. Minor skin dehiscence not involv-
ing the graft is common and usually responds to conserva-
tive measures, such as local dressing care, elastic compres-
sion, and restriction of weight bearing. Serious wound
problems, including infection with graft exposure, occa-
sionally occur and may require more complex treatment,
such as myocutaneous free tissue transfer and skin grafting.
RESULTS
From January 1990 through January 2000, 1032 by-
passes to the DP artery were performed in 864 patients.
This comprised 27.6% of the 3731 infrainguinal arterial
reconstructions performed in that time period (Table I).
Patient characteristics are shown in Table II. The mean age
was 66.8 years, and 70% of the patients were male. More
than 90% had diabetes mellitus. Hypertension and coro-
nary artery disease were present in most patients. Nearly
17% had some degree of renal insufficiency, and 11% were
undergoing dialysis at the time of surgery.
The indications for surgery are also listed in Table II.
All operations were performed for limb-threatening isch-
emia or to salvage a failing bypass graft. The most common
indication was a nonhealing ischemic foot ulcer. Thirty
percent of patients had foot infection in addition to isch-
emia.
All but two procedures were performed with autolo-
gous vein. The types of conduit and inflow arteries are listed
in Table III. Seven patients had a DP bypass performed
distal to a more proximal prosthetic bypass, including two
aortofemoral and two iliofemoral bypasses done previously,
two femoral popliteal bypasses done simultaneously, and
one other bypass in which the exact configuration was
unknown. The most commonly performed procedure was a
popliteal to DP arterial bypass with nonreversed saphenous
vein. In situ vein grafts were performed in approximately
27% of cases. Alternative vein conduits were necessary in
approximately 20%, of which most were arm vein grafts.
Ten deaths (0.97%) occurred within 30 days of surgery.
Forty-three of 1032 grafts (4.2%) failed within 30 days.
Thirty-one patients (3.0%) had symptomatic myocardial
infarction or acute congestive heart failure. The incidence
rate of clinically “silent” myocardial infarction was un-
known because routine cardiac enzymes were not drawn.
Three patients each had acute strokes and acute renal
failure. Severe limb-threatening postoperative wound in-
fections occurred in 21 extremities (2.0%), two of which
resulted in graft infections and loss of the graft and limb.
Less severe wound infections occurred more frequently.
The precise number could not be determined from avail-
able data in the database. Sixty-eight patients (6.6%) under-
Table I. Outflow target arteries in 3731 infrainguinal
arterial bypass procedures performed from 1990 to 2000
No. of arteries
Above-knee popliteal 415
Below-knee popliteal 508
Anterior tibial 486
Posterior tibial 557
Peroneal 349
Plantar 112
DP 1032
Tibial-peroneal trunk 71
Previous graft 129
Other 72
Total 3731
Table II. Clinical characteristics and surgical indications
for patients undergoing DP bypass
No. of patients
Demographics
Age (mean; y) 66.8
Male gender 597 (69.10%)
Diabetes mellitus 794 (91.90%)
Hypertension 534 (61.80%)
CAD 405 (46.90%)
Prior MI 259 (30.00%)
CHF 195 (22.60%)
CABG 183 (21.20%)
Creatinine  2 mg/dL 144 (16.70%)
Dialysis 97 (11.20%)
Current smoker 94 (10.90%)
Indications
Nonhealing ulcer 809 (78.40%)
Gangrene 380 (36.80%)
Infection 302 (29.30%)
Rest pain 226 (21.90%)
Failing bypass graft 34 (3.30%)
CAD, Coronary artery disease; MI, myocardial infarction; CHF, congestive
heart failure; CABG, coronary artery bypass grafting.
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went unexpected early reoperation for graft thrombosis,
postoperative bleeding, or infection. Thirteen of 42 peri-
operative graft thromboses were successfully revised. Nine-
teen could not be revised and resulted in eventual major
amputation, and 10 additional failed and unrevised grafts
did not result in loss of the foot. In the follow-up period,
which extended from 1 to 120 months (mean, 23.6
months), primary patency, secondary patency, and limb-
salvage were 56.8%, 62.7%, and 78.2% at 5 years and 37.7%,
41.7%, and 57.7%, at 10 years. Patient survival rates were
48.6% and 23.8% at 5 and 10 years, respectively, and did
not differ significantly between male and female patients.
The primary graft patency rate was 46.4% for female pa-
tients versus 61.6% for male patients at 5 years (P  .009).
Patients with diabetes faired better than patients without
diabetes. The 5-year secondary patency rate for patients
with diabetes was 65.9% versus 56.3% for patients without
diabetes at 4 years (P  .04). Saphenous vein grafts per-
formed better than all other conduits, with a secondary
patency rate of 67.6% versus 46.3% at 5 years (P  .0001).
These results are summarized in Figs 1 to 4. Univariate
analysis (Table IV) identified five of 31 clinical factors
(presence of ulcer, sepsis, graft occlusion as the indication
for DP bypass, revision of the graft, use of saphenous vein as
conduit, and length of stay) that had a significant effect on
the likelihood of graft patency at 1 year after surgery. On
multivariate analysis, however, only increased length of stay
and graft occlusion as the indication for DP bypass were
independently predictive of worse graft patency, and the
use of saphenous vein as the conduit was predictive of
better graft patency (Table V).
DISCUSSION
This study shows that DP bypass for foot ischemia in
patients with diabetes mellitus is a safe, effective, and dura-
ble procedure. Graft patency and limb salvage rates are
comparable with more proximal infrainguinal arterial re-
constructions and when performed with saphenous vein
have excellent durability with patency for 10 years or longer
Table III. Conduits and inflow arteries
No. of patients
Conduit
Nonreversed saphenous 317 (30.70%)
In situ saphenous 273 (26.40%)
Reversed saphenous 235 (22.80%)
Arm vein 170 (16.50%)
Composite vein 25 (2.40%)
Lesser sphenous 10 (1.00%)
PTFE 2 (0.20%)
Inflow artery
Below-knee popliteal 426 (41.30%)
Common femoral 294 (28.50%)
Above-knee popliteal 124 (12.00%)
Superficial femoral 114 (11.00%)
Vein graft 49 (4.70%)
Prosthetic graft 7 (0.70%)
Tibial artery 6 (0.60%)
Iliac artery 6 (0.60%)
Deep femoral artery 6 (0.60%)
PTFE, Polytetrafluoroethylene.
Fig 1. Primary (A), assisted primary (B), and secondary (C)
patency rates of all DP bypass grafts. Standard error was less than
10% at all time intervals.
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in some patients. Pedal bypass is well suited to the anatomic
pattern of atherosclerosis most commonly seen in patients
with diabetes mellitus (tibial/peroneal artery occlusion,
minimal involvement of the aortoiliac segment and super-
ficial femoral artery, and sparing of the foot arteries espe-
cially the DP artery). For many patients, it may be the only
outflow target artery available for bypass and should always
be included in the preoperative arteriogram.
Although pedal bypass represents the most extreme
form of distal arterial reconstruction, it need not be a
technical tour de force. Indeed our enthusiasm and liberal
use of pedal bypass in more than 1000 procedures is pred-
icated not only on its efficacy but also its simplicity. The
relatively superficial location of the DP artery makes it easily
accessible—an advantage making anastomosis to “good”
arteries straightforward and those to “bad” arteries (calci-
fied, small caliber, etc) easier. Moreover, the usual pattern
of atherosclerosis seen in diabetes makes it possible to use
distal inflow, usually at the popliteal artery, more than 50%
of the time (53.3% in this study). The advantages of a
distally based inflow procedure cannot be overemphasized.
It requires less vein conduit, allows the surgeon the oppor-
tunity to perform the procedure with the best segment of
conduit, and avoids groin dissections in obese patients and
lower leg dissections in patients with venous stasis problems
or edema. Most importantly, as shown in several re-
ports,21-23 these advantages do not come with the price of
reduced long-term patency from progression of superficial
femoral arterial disease. The fact that all but two pedal
bypasses were performed with vein grafts shows that if an
aggressive effort is made, especially when combined with
use of distal inflow arteries, usage of prosthetic grafts can be
avoided for most if not all pedal bypasses. The best results
can be expected when saphenous vein is used as a conduit,
but even alternative vein conduits, most of which were arm
vein grafts in this study, are preferable because they per-
formed far better than the expected performance of pros-
thetic grafts to this level.24 Preparation of alternative con-
duits can be challenging but in our experience is aided by
the use of angioscopy, which has also proven useful in
preparation of in situ saphenous grafts.
These results provide further evidence against the exis-
tence of “small vessel disease.”25 DP bypass grafts could
neither remain patent nor heal ischemic foot ulcers if the
microcirculation was occluded. Although refuted in ana-
tomic,1,26 physiologic,1,27,28 and clinical studies,29 includ-
ing this report, this antiquated concept persists to this day
and continues to result in amputations being performed
unnecessarily for foot ischemia. No patient with diabetes
and foot ischemia should be considered to have an unsal-
Fig 2. Limb salvage for all DP bypasses. Standard error was less
than 10% at all time intervals.
Fig 3. Patient mortality rate for all DP bypass grafts. Standard
error was less than 10% at all time intervals.
Fig 4. Primary patency rate of greater saphenous vein (GSV)
versus all other conduits. Difference is significant (P  .0001).
Standard error was less than 10% at all time intervals.
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vageable condition and undergo amputation on the basis of
the diagnosis of small vessel occlusive disease alone.
The low perioperative mortality rate and clinical cardiac
morbidity rate refute the finding that diabetes is a risk factor
for perioperative cardiac morbidity.30,31 Although the in-
cidence rate of myocardial infarction is probably underesti-
mated because of the lack of routine postoperative cardiac
enzyme determination in this study, the perioperative
death and clinically apparent cardiac complications rates
were low. Our results are consistent with the findings of
Axelrod et al32 and our larger study that analyzed outcomes
of more than 6000 major arterial reconstructions, where
diabetes was not found to be an independent risk factor for
early cardiac complications or death.33 Moreover, this re-
port adds further support to the concept that diabetes alone
does not portend a worse outcome for arterial reconstruc-
tive surgery.34-38 Patients with diabetes actually had better
graft patency and limb salvage rates in this study, and
diabetes was not predictive reduced patency in multivariate
analysis. We were surprised to find that graft patency at 5
years was worse in women. Previous studies39,40 have con-
cluded that women do as well as men with lower extremity
bypass; however, Magnant et al41 found that female gender
was predictive of lower graft patency. They postulated that
smaller caliber arteries or vein grafts may have caused worse
patency rates in women, although they had no specific data
to support this possibility. We likewise have no data on any
comparative differences in the size of arteries in men and
women that may have existed. Moreover, although multi-
variate analysis at 1 and 5 years showed a trend suggesting
male gender was associated with better patency with odds
ratios of 1.16 and 1.2, respectively, this result did not reach
statistical significance (P  .39 and .48). We cannot fully
explain our results and continue to believe that the expec-
tations for women with DP bypass should be no different
than for men.
We recognize that many groups have reported equiva-
lent results in limb salvage, with much lower rates of usage
Table IV. Results of univariate analysis of factors influencing graft patency at 1 year after DP bypass
Clinical factor P value
Gender .426
Diabetes mellitus .988
Neuropathy .161
Tobacco use .380
CAD .404
CHF .375
Angina .486
HTN .398
Arrythmia .724
Previous MI .115
CABG .786
Previous PTCA .162
Renal dz .147
Creatinine  2 mg/dL .065
HD .138
CAPD .270
Stroke .083
Any limb ischemia .850
Ulcer .024 (.05)*
Gangrene .308
Infection .093
Sepsis .030 (.05)*
Abscess .958
Rest pain .661
Claudication .998
Failing graft .444
Bypass for occluded graft .000 (.0001)*
Revised graft .000 (.0001)*
Greater saphenous vein .000 (.0001)*
Age .061
Length of stay  10 days .000 (.0001)*
*Significant variables.
CAD, Coronary artery disease; CHF, congestive heart failure; HTN, hypertension; MI, myocardial infarction; CABG, coronary artery bypass grafting; PTCA,
percutaneous transluminal coronary angioplasty; dz, disease; HD, hemodialysis; CAPD, peritoneal dialysis.
Table V. Results of multivariate analysis of variables
independently affecting graft patency at 1 year
Wald test
(P value)
Odds
ratio 95% CI
Length of stay  10 d .0001 0.95 0.93-0.98
Bypass for graft occlusion .05 0.38 0.17-0.89
Greater saphenous vein .005 1.82 1.25-2.65
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of pedal arterial reconstruction, and in two studies, peroneal
artery grafts performed as well as pedal grafts for patients with
similar indications.5,6 In our practice, DP bypass appeared to
be the principal factor resulting in a decrease in the number of
both major and minor amputations performed for ischemia
over a 10-year period.42 The advantage of DP bypass seems
intuitive in that restoration of arterial perfusion to the ischemic
diabetic foot is direct, in close proximity to the ischemic lesion
and not dependent on terminal branches or collaterals. More
importantly, when given equal consideration to popliteal or
crural outflow targets, DP bypass adds another potential by-
pass option, resulting in the ability to perform a limb-sparing
arterial reconstruction in a group of patients previously treated
only with amputation. On the basis of the results of this study,
DP bypass will continue to be a mainstay in our treatment of
ischemic foot salvage in patients with diabetes mellitus.
In summary, pedal arterial reconstruction has proven to
be a safe, simple, durable, and highly effective procedure in
a large patient cohort with advanced limb ischemia of which
more than 90% had diabetes mellitus. Pedal bypass is par-
ticularly well suited for ischemic foot salvage in these pa-
tients because of the pattern of atherosclerosis most com-
monly seen. The use of short vein grafts from distal inflow
sites can simplify the procedure and is possible in most
patients. DP bypass should be in the armamentarium of all
vascular surgeons treating limb ischemia in patients with
diabetes mellitus.
We thank three former colleagues, Gary W. Gibbons,
MD, Cameron Akbari, MD, and Dorthy V. Freeman, MD,
who performed a number of the procedures included in this
study. We thank our database manager, Lynn Francis, and
administrative assistant, Antoinette Perry, for their assis-
tance in the preparation of the manuscript. We thank Nikhil
Kansal, MD, and Malachi Sheahan, MD, for statistical
analysis.
REFERENCES
1. Conrad MC. Large and small artery occlusion in diabetics and nondia-
betics with severe vascular disease. Circulation 1967;36:83-91.
2. Pomposelli FB Jr, Marcaccio EJ, Gibbons GW, Campbell DR, Freeman
DV, Burgess AM, et al. Dorsalis pedis arterial bypass: durable limb
salvage for foot ischemia in patients with diabetes mellitus. J Vasc Surg
1995;21:375-84.
3. Tannenbaum GA, Pomposelli FB Jr, Marcaccio EJ, Gibbons GW,
Campbell DR, Freeman DV, et al. Safety of vein bypass grafting to the
dorsal pedal artery in diabetic patients with foot infections. J Vasc Surg
1992;15:982-90.
4. Berceli SA, Chan AK, Pomposelli FB Jr, Gibbons GW, Campbell DR,
Akbari CM, et al. Efficacy of dorsal pedal artery bypass in limb salvage
for ischemic heel ulcers. J Vasc Surg 1999;30:499-508.
5. Darling RC III, Chang BB, Shah DM, Leather RP. Choice of peroneal
or dorsalis pedis artery bypass for limb salvage. Semin Vasc Surg 1997;
10:17-22.
6. Abou-Zamzam AM Jr, Moneta GL, Lee RW, Nehler MR, Taylor LM
Jr, Porter JM. Peroneal bypass is equivalent to inframalleolar bypass for
ischemic pedal gangrene. Arch Surg 1996;131:894-9.
7. Andros G, Harris RW, Salles-Cunha SX, Dulawa LB, Oblath RW,
Apyan RL. Bypass grafts to the ankle and foot. J Vasc Surg 1988;7:785-
94.
8. Plecha EJ, Lee C, Hye RJ. Factors influencing the outcome of paramal-
leolar bypass grafts. Ann Vasc Surg 1996;10:356-60.
9. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et
al. Recommended standards for reports dealing with lower extremity
ischemia: revised version. J Vasc Surg 1997;26:517-38.
10. Crandall RC, Wagner FW Jr. Partial and total calcanectomy: a review of
thirty-one consecutive cases over a ten-year period. J Bone Joint Surg
Am 1981;63:152-5.
11. Baumhauer JF, Fraga CJ, Gould JS, Johnson JE. Total calcanectomy for
the treatment of chronic calcaneal osteomyelitis. Foot Ankle Int 1998;
19:849-55.
12. Pomposelli FB Jr, Jepsen SJ, Gibbons GW, Campbell DR, Freeman
DV, Miller A, et al. Efficacy of the dorsal pedal bypass for limb salvage
in diabetic patients: short-term observations. J Vasc Surg 1990;11:745-
52.
13. Blakeman BM, Littooy FN, Baker WH. Intra-arterial digital subtraction
angiography as a method to study peripheral vascular disease. J Vasc
Surg 1986;4:168-73.
14. Pomposelli FB Jr, Jepsen SJ, Gibbons GW, Campbell DR, Freeman
DV, Gaughan BM, et al. A flexible approach to infrapopliteal vein grafts
in patients with diabetes mellitus. Arch Surg 1991;126:724-9.
15. Miller A, Stonebridge PA, Jepsen SJ, Tsoukas A, Gibbons GW, Pom-
poselli FB Jr, et al. Continued experience with intraoperative angios-
copy for monitoring infrainguinal bypass grafting. Surgery 1991;109(3
Pt 1):286-93.
16. Kwolek CJ, Miller A, Stonebridge PA, Lavin P, Lewis KP, Tannenbaum
GA, et al. Safety of saline irrigation for angioscopy: results of a prospec-
tive randomized trial. Ann Vasc Surg 1992;6:62-8.
17. Miller A, Stonebridge PA, Tsoukas AI, Kwolek CJ, Brophy CM, Gib-
bons GW, et al. Angioscopically directed valvulotomy: a new valvu-
lotome and technique. J Vasc Surg 1991;13:813-21.
18. Faries PL, Arora S, Pomposelli FB Jr, Pulling MC, Smakowski P, Rohan
DI, et al. The use of arm vein in lower-extremity revascularization:
results of 520 procedures performed in eight years. J Vasc Surg 2000;
31(1 Pt 1):50-9.
19. Marcaccio EJ, Miller A, Tannenbaum GA, Lavin PT, Gibbons GW,
Pomposelli FB Jr, et al. Angioscopically directed interventions improve
arm vein bypass grafts. J Vasc Surg 1993;17:994-1004.
20. Miller A, Marcaccio EJ, Tannenbaum GA, Kwolek CJ, Stonebridge PA,
Lavin PT, et al. Comparison of angioscopy and angiography for moni-
toring infrainguinal bypass vein grafts: results of a prospective random-
ized trial. J Vasc Surg 1993;17:382-98.
21. Cantelmo NL, Snow JR, Menzoian JO, LoGerfo FW. Successful vein
bypass in patients with an ischemic limb and a palpable popliteal pulse.
Arch Surg 1986;121:217-20.
22. Ascer E, Veith FJ, Gupta SK, White SA, Bakal CW, Wengerter K, et al.
Short vein grafts: a superior option for arterial reconstructions to poor
or compromised outflow tracts? J Vasc Surg 1988;7:370-8.
23. Stonebridge PA, Tsoukas AI, Pomposelli FB Jr, Gibbons GW, Camp-
bell DR, Freeman DV, et al. Popliteal-to-distal bypass grafts for limb
salvage in diabetics. Eur J Vasc Surg 1991;5:265-9.
24. Veith FJ, Gupta SK, Ascer E, White-Flores S, Samson RH, Scher LA, et
al. Six-year prospective multicenter randomized comparison of autolo-
gous saphenous vein and expanded polytetrafluoroethylene grafts in
infrainguinal arterial reconstructions. J Vasc Surg 1986;3:104-14.
25. Goldenberg SG, Joshi RA. Nonatheromatous peripheral vascular dis-
ease of the lower extremity in diabetes mellitus. Diabetes 1959;8:261-
73.
26. Strandness DE, Gibbons GE. Combined clinical and pathological study
of diabetic and nondiabetic peripheral arterial disease. Diabetes 1964;
13:366-72.
27. Barner HB, Kaiser GC, Willman VL. Blood flow in the diabetic leg.
Circulation 1971;43:391-4.
28. Irwin ST, Gilmore J, McGrann S, Hood J, Allen JA. Blood flow in
diabetics with foot lesions due to “small vessel disease.” Br J Surg
1988;75:1201-6.
29. LoGerfo FW, Coffman JD. Current concepts. Vascular and microvas-
cular disease of the foot in diabetes. Implications for foot care. N Engl
J Med 1984;311:1615-9.
30. Goldman L, Caldera DL, Nussbaum SR, Southwick FS, Krogstad D,
Murray B, et al. Multifactorial index of cardiac risk in noncardiac
surgical procedures. N Engl J Med 1977;297:845-50.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 2 Pomposelli et al 313
31. L’Italien GJ, Cambria RP, Cutler BS, Leppo JA, Paul SD, Brewster DC,
et al. Comparative early and late cardiac morbidity among patients
requiring different vascular surgery procedures. J Vasc Surg 1995;21:
935-44.
32. Axelrod DA, Upchurch GR Jr, DeMonner S, Stanley JC, Khuri S, Daley
J, et al. Perioperative cardiovascular risk stratification of patients with
diabetes who undergo elective major vascular surgery. J Vasc Surg
2002;35:894-901.
33. Hamdan AD, Saltzberg SS, Sheahan M, Froelich J, Akbari CM, Camp-
bell DR, et al. Lack of association of diabetes with increased postoper-
ative mortality and cardiac morbidity: results of 6565 major vascular
operations. Arch Surg 2002;137:417-21.
34. Rutherford RB, Jones DN, Bergentz SE, Bergqvist D, Comerota AJ,
Dardik H, et al. Factors affecting the patency of infrainguinal bypass. J
Vasc Surg 1988;8:236-46.
35. Shah DM, Chang BB, Fitzgerald KM, Kaufman JL, Leather RP. Dura-
bility of the tibial artery bypass in diabetic patients. Am J Surg 1988;
156:133-5.
36. Robinson KD, Sato DT, Gregory RT, Gayle RG, DeMasi RJ, Parent FN
III, et al. Long-term outcome after early infrainguinal graft failure. J
Vasc Surg 1997;26:425-38.
37. Panneton JM, Gloviczki P, Bower TC, Rhodes JM, Canton LG,
Toomey BJ. Pedal bypass for limb salvage: impact of diabetes on
long-term outcome. Ann Vasc Surg 2000;14:640-7.
38. Gahtan V, Harpavat M, Roberts AB, Kerstein MD. Impact of diabetes
mellitus on infrainguinal bypass grafting. J Diabetes Complications
1998;12:197-200.
39. Harris EJ Jr, Taylor LM Jr, Moneta GL, Porter JM. Outcome of
infrainguinal arterial reconstruction in women. J Vasc Surg 1993;18:
627-36.
40. Belkin M, Conte MS, Donaldson MC, Mannick JA, Whittemore AD.
The impact of gender on the results of arterial bypass with in situ greater
saphenous vein. Am J Surg 1995;170:97-102.
41. Magnant JG, Cronenwett JL, Walsh DB, Schneider JR, Besso SR,
Zwolak RM. Surgical treatment of infrainguinal arterial occlusive dis-
ease in women. J Vasc Surg 1993;17:67-78.
42. LoGerfo FW, Gibbons GW, Pomposelli FB Jr, Campbell DR, Miller A,
Freeman DV, et al. Trends in the care of the diabetic foot. Expanded
role of arterial reconstruction. Arch Surg 1992;127:617-21.
Submitted Jun 17, 2002; accepted Oct 1, 2002.
DISCUSSION
Dr Kevin G. Burnand (London, United Kingdom). One of
the results that you have not given us is how many toes and forefeet
you had to amputate. Have you done an analysis on forefoot
amputation or digital amputation? Would that be an independent
risk factor in terms of outcome?
Dr Frank B. Pomposelli. I do not have precise data, al-
though I suspect that there is actually a large number of patients
who had some sort of a minor foot amputation in the study,
probably about 40% to 50%.
Transmetatarsal amputation has not been a risk factor for
pedal graft failure. They actually will heal quite well, and the graft
will remain patent.
Dr George Andros (Encino, Calif). I am absolutely drunk
with delight. This is a cornucopia of information. I think it is
probably the most important diabetic vascular paper in the 30-plus
years that I have been coming here. It is just an amazing series,
Frank.
A few questions. Do you rely on MRA? We still do angios.
MRA has been talked about a lot. Would you comment?
We still probably do more bypasses to the posterior circula-
tion, and we are seeing an awful lot of heel ulcers and would
actually go to the heel, plantar, or posterior tibial vessel if we could
because of heel ulcers.
You talk about not having weightbearing for 2 to 7 days. Is
that because of the bypass or the ulcer?
You do a lot of bypasses for rest pain. Very few of our patients
have rest pain because of their diabetic neuropathic feet.
And finally, we have, in this country, an amputation rate that I
think is a national problem. Why are not we making an impact on
that amputation rate if these operations are available?
Dr Pomposelli. Thank you, Dr Andros. We use MRA for
diagnostic evaluation, but quite infrequently. We still rely mostly
on intraarterial digital subtraction angiography. We limit the use of
MRA to those patients in whom there is some strong contraindi-
cation to contrast.
Our experience has been that plantar artery bypass has a
different outcome from pedal bypass, which is why they are not
included here. We have worse results with that procedure and
avoid it whenever possible. The plantar artery may be a poorer
outflow tract. Far more often, the dorsalis pedis is patent or a better
artery. Dr Scott Burcelli analyzed our results with pedal bypass and
demonstrated that healing occurred in about 80% of patients with
heel ulcers. Very extensive heel ulcers did not heal, although many
did even though the anterior circulation via the pedal artery was the
pronciple source of blood supply.
We restrict weightbearing to try to decrease the amount of
perioperative swelling. On the average, absolute non-weight bear-
ing is maintained for 2 days, but longer periods of non-weight
bearing are maintained in patients with plantar ulcers or open foot
wounds or for other reasons.
Rest pain is an indication for pedal bypass in some patients
with diabetes. It is infrequent, and it was not, I think, a large
percentage of patients. Usually we extend bypass to the dorsalis
pedis artery in this circumstance because there is no other outflow
target available.
Major amputation remains a significant complication of dia-
betes mellitus. While some are probably unavoidable, we continue
to feel that many of those done for ischemia result from undo
pessimism due to misconceptions such as small vessel disease. If
nothing else, this paper demonstrates that arterial reconstruction is
possible and works well in most patients with ischemic foot com-
plications of diabetes mellitus. All should be evaluated for bypass
prior to amputation.
Dr Bruce M. Elliott (Charleston, SC). All too frequently the
patient requiring limb salvage presents with limited acceptable
targets for bypass, and they often distill down to a choice between
the dorsalis pedis or the peroneal as the only acceptable targets.
Under what circumstances would you actually prefer to use the
peroneal as your target for bypass? And in patients with established
forefoot gangrene, has bypass, in your experience, to targets other
than the pedal vessel resulted in comparable foot salvage?
Dr Pomposelli. We perform dorsalis pedis bypass frequently
in preference to the peroneal bypass. Our goal with tissue loss in
the foot is to try to restore a palpable foot pulse. If a femoral-
popliteal or a tibial bypass will do achieve that goal, we will not do
a dorsalis pedis graft. If the dorsalis pedis graft is a poor quality
vessel on the arteriogram, if there is extensive forefoot infection or
gangrene, especially where we might do the anastomosis, we will
not do a pedal graft. If we do not have adequate venous conduit to
reach to the foot, we will look for another suitable more proximal
outflow target. In that case, oftentimes a peroneal may be the only
other alternative and we will bypass to the peroneal. Pedal bypass is
also a very poor operation for claudication. If the only choice was
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pedal or peroneal, I would definitely bypass the peroneal in that
situation.
Dr Peter R. F. Bell (Leicester, United Kingdom). Just three
questions. As far as inflow is concerned from low-down takeoffs,
do you eyeball it or how do you measure the adequate inflow?
Secondly, do you do the amputation of the toes, or whatever,
at the same time as the procedure?
And thirdly, do you use any long-term anticoagulation at all?
Dr Pomposelli. Usually the arteriogram will demonstrate
whether or not the superficial femoral artery is reasonable. If there
is any question, we will measure pressure at the area of the proximal
anastomosis in the operating room and compare it with the radial
arterial pressure. We consider a gradient of less than 5 to be
insignificant. If conduit is very limited and we are committed to a
pedal bypass, we may accept more disease, or in some cases when a
popliteal artery segment is patent, we will perform an above-knee
fem-pop with prosthetic graft and then the pedal bypass with vein
in sequence.
Minor amputation at the time of bypass is a matter of individ-
ual preference. I do it infrequently; others in our division do it
regularly.
These patients are not routinely anticoagulated with warfarin.
The majority of them are on aspirin, and occasionally some receive
another antiplatelet agent.
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